Cover Image
市場調查報告書

Sorafenib的中國市場:2010年∼2019年

Investigation Report on China Sorafenib Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 335239
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Sorafenib的中國市場:2010年∼2019年 Investigation Report on China Sorafenib Market, 2010-2019
出版日期: 2015年07月10日 內容資訊: 英文 20 Pages
簡介

2014年中國的Sorafenib銷售額為1億6,500萬人民幣,從前一年的1億4,700萬人民幣增加12.24%。該國由於環境污染的惡化和生活方式的變化,肝癌罹患率有擴大趨勢,使Sorafenib的需求劇增。現在,中國市場可取得的Sorafenib全部為Bayer AG製。

本報告提供中國的Sorafenib市場的相關調查、Sorafenib的功效與效果、中國市場中專利及核准狀況、銷售額&銷售量的變化與預測、價格趨勢、主要製造商與市場佔有率、競爭環境與其展望、主要製造商簡介等彙整資料。

第1章 Sorafenib的相關概念

  • 適應
  • 全球市場的銷售情形

第2章 中國的Sorafenib的市場簡介

  • 專利及核准資訊
  • 主要製藥公司
  • 市場規模

第3章 中國的Sorafenib銷售情形調查

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售數

第4章 中國的Sorafenib的主要製藥公司市場佔有率調查

  • 以銷售額為基礎的市場佔有率
  • 以銷售量為基礎的市場佔有率

第5章 中國的Sorafenib的劑型的相關調查

  • 各劑型的市場佔有率:以銷售額為基礎
  • 各劑型的市場佔有率:以銷售量為基礎

第6章 中國醫院的Sorafenib的標準價格

  • Bayer Pharma AG (商品名:Nexavar)

第7章 中國市場中Sorafenib的主要製藥公司

第8章 Sorafenib市場預測

  • 市場規模的預測
  • 競爭情形的預測
目錄
Product Code: 1507270

The incidence of liver cancer and kidney cancer in China grows gradually. According to the Guidelines for Kidney Cancer Diagnosis and Treatment in China (the 2013 version), kidney cancer accounts for 2%-3% of adult malignant tumors in China and reports an obvious rise in incidence in recent years in China. Kidney cancer has surpassed bladder cancer to become the first in death related with urological tumors with its incidence growing at an average rate of 6.5% during the past two decades. According to the World Cancer Report 2014, China ranked first in the new cases of liver cancer and its death toll. Currently, liver cancer, with 0.257 in 1 million suffering from it, has become the third malignant tumor after stomach cancer and lung cancer in terms of mortality. As a novel small molecular multi-targeted inhibitor of tyrosine kinase, sorafenib is approved by FDA to treat unresectable advanced renal cell carcinoma and unresectable or metastasized primary hepatocellular carcinoma. Co-developed by Bayer and Onyx Pharmaceuticals, sorafenib got imported drug license in 2006 and was approved by China Food and Drug Administration to enter the market for the treatment of liver cancer in 2008.

According to CRI's survey on 20 sample hospitals in key regions in China, sales value of sorafenib was CNY 147 million in 2013 and CNY 165 million in 2014, increasing 12.24% year on year.

With the degradation of environmental pollution and changes in lifestyle, the incidence of liver cancer keeps rising. Hence the vast demand for sorafenib in China. Currently, sorafenib in the Chinese market all come from Bayer AG i.e. Bayer enjoys a market share of 100%.

Readers can get at least the following information from this report:

  • market size of sorafenib in China
  • major manufacturers of sorafenib in Chinese market
  • retail price of sorafenib in China
  • market outlook of sorafenib in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-tumor drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Sorafenib

  • 1.1. Indication
  • 1.2. Sales in Global Market

2. Market Profile of Sorafenib in China

  • 2.1. Patent and Approval Information of Sorafenib in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Sorafenib in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Sorafenib in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Sorafenib in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Sorafenib in Chinese Hospitals in 2014

  • Bayer Pharma AG (Trade Name: Nexavar)

7. Major Manufacturers of Sorafenib in Chinese Market, 2010-2014

8. Outlook of Sorafenib Market in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Status of Sorafenib in China
  • Chart Approval Information of Sorafenib in China
  • Chart Sales Status of Sorafenib in China
  • Chart Sales Value of Sorafenib in China, 2010-2014
  • Chart Sales Value of Sorafenib in Some Regions in China, 2010-2014
  • Chart Sales Volume of Sorafenib in China, 2010-2014
  • Chart Sales Volume of Sorafenib in Some Regions in China, 2010-2014
  • Chart Market Share of Sorafenib Manufacturers for Sales Value in China, 2010-2014
  • Chart Market Share of Sorafenib Manufacturers for Sales Volume in China, 2010-2014
  • Chart Sales Volume and Market Share of Bayer Pharma AG in China, 2010-2014
  • Chart Sales Value and Market Share of Sorafenib Tablets in China, 2010-2014
  • Chart Sales Volume and Market Share of Sorafenib Tablets in China, 2010-2014
  • Chart Price of Sorafenib Made by Bayer Pharma AG in Some Chinese Cities in 2014
Back to Top